JPH09500620A - 極小の運動遮断で鎮痛効果を示す医薬の製造におけるロピバカインの使用 - Google Patents
極小の運動遮断で鎮痛効果を示す医薬の製造におけるロピバカインの使用Info
- Publication number
- JPH09500620A JPH09500620A JP7502687A JP50268795A JPH09500620A JP H09500620 A JPH09500620 A JP H09500620A JP 7502687 A JP7502687 A JP 7502687A JP 50268795 A JP50268795 A JP 50268795A JP H09500620 A JPH09500620 A JP H09500620A
- Authority
- JP
- Japan
- Prior art keywords
- ropivacaine
- weight
- minimal
- manufacture
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 title claims abstract description 28
- 229960001549 ropivacaine Drugs 0.000 title claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 239000003814 drug Substances 0.000 title claims description 4
- 230000000202 analgesic effect Effects 0.000 title description 6
- 229940079593 drug Drugs 0.000 title 1
- 230000001953 sensory effect Effects 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 208000002193 Pain Diseases 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 238000001802 infusion Methods 0.000 description 13
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 11
- 229960003150 bupivacaine Drugs 0.000 description 11
- 230000000699 topical effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 6
- 229940035676 analgesics Drugs 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000001144 postural effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001432 effect on motor function Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960001813 ropivacaine hydrochloride Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Insulation, Fastening Of Motor, Generator Windings (AREA)
- Electromechanical Clocks (AREA)
- Particle Accelerators (AREA)
- Air Conditioning Control Device (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ロピバカインの濃度が0.5重量%より低い感覚遮断及び極小の運動遮断を示 す医薬の製造におけるロピバカインの薬学的に許容される塩の使用。 2.ロピバカインがその塩酸塩の形である請求項1記載の使用。 3.ロピバカインの濃度が0.01から0.45重量%までである請求項1記載の使用。 4.ロピバカインの濃度が0.2重量%である請求項3記載の使用。 5.極小の運動遮断を伴う痛み軽減を必要とする患者の治療方法であって、それ によりロピバカインの薬学的に許容される塩の低い有効量を使用する方法。 6.極小の運動遮断を伴う急性の痛み治療に使用するための医薬製剤であって、 ここで活性成分が0.5重量%より低い濃度のロピバカインの薬学的に許容される 塩である医薬製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9302218-4 | 1993-06-28 | ||
SE19939302218A SE9302218D0 (sv) | 1993-06-28 | 1993-06-28 | New use |
PCT/SE1994/000496 WO1995000148A1 (en) | 1993-06-28 | 1994-05-26 | Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09500620A true JPH09500620A (ja) | 1997-01-21 |
JP3725541B2 JP3725541B2 (ja) | 2005-12-14 |
Family
ID=20390432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50268795A Expired - Fee Related JP3725541B2 (ja) | 1993-06-28 | 1994-05-26 | ロピバカインを含有する医薬製剤 |
Country Status (33)
Country | Link |
---|---|
US (2) | US5670524A (ja) |
EP (1) | EP0706395B1 (ja) |
JP (1) | JP3725541B2 (ja) |
CN (1) | CN1074918C (ja) |
AT (1) | ATE216237T1 (ja) |
BR (1) | BR9406865A (ja) |
CA (1) | CA2165446C (ja) |
CZ (1) | CZ283300B6 (ja) |
DE (2) | DE706395T1 (ja) |
DK (1) | DK0706395T3 (ja) |
EE (1) | EE03205B1 (ja) |
ES (1) | ES2099048T3 (ja) |
FI (1) | FI956269A (ja) |
GR (1) | GR970300013T1 (ja) |
HK (1) | HK1010344A1 (ja) |
HU (1) | HU218949B (ja) |
IL (1) | IL110006A (ja) |
IS (1) | IS4174A (ja) |
LT (1) | LT3449B (ja) |
LV (1) | LV12918B (ja) |
MY (1) | MY119360A (ja) |
NO (1) | NO955313L (ja) |
NZ (1) | NZ268110A (ja) |
PH (1) | PH31258A (ja) |
PL (1) | PL175518B1 (ja) |
PT (1) | PT706395E (ja) |
RU (1) | RU2152215C1 (ja) |
SA (1) | SA94150010B1 (ja) |
SE (1) | SE9302218D0 (ja) |
SG (1) | SG49078A1 (ja) |
SK (1) | SK280111B6 (ja) |
TW (1) | TW285640B (ja) |
WO (1) | WO1995000148A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016508956A (ja) * | 2012-05-10 | 2016-03-24 | セリックスビオ プライヴェート リミテッド | 局所疼痛の治療のための組成物と治療法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9302218D0 (sv) * | 1993-06-28 | 1993-06-28 | Ab Astra | New use |
US5945435A (en) * | 1997-07-21 | 1999-08-31 | Darwin Discovery Limited | Levobupivacaine and its use |
US20060270708A1 (en) * | 2005-05-25 | 2006-11-30 | Navinta Llc | Novel process for preparation of isotonic aqueous injection of ropivacaine |
USRE46397E1 (en) | 2007-11-07 | 2017-05-09 | Svip5 Llc | Slow release of organic salts of local anesthetics for pain relief |
RU2678433C2 (ru) | 2012-05-10 | 2019-01-29 | Пейнреформ Лтд. | Депо-составы гидрофобного активного ингредиента и способы их получения |
KR20150119468A (ko) | 2013-02-28 | 2015-10-23 | 더미라, 인코포레이티드 | 글리코피롤레이트 염 |
US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3379266D1 (en) * | 1983-08-01 | 1989-04-06 | Astra Laekemedel Ab | L-n-n-propylpipecolic acid-2,6-xylidide and method for preparing the same |
SE9302218D0 (sv) * | 1993-06-28 | 1993-06-28 | Ab Astra | New use |
-
1993
- 1993-06-28 SE SE19939302218A patent/SE9302218D0/xx unknown
-
1994
- 1994-05-26 ES ES94919912T patent/ES2099048T3/es not_active Expired - Lifetime
- 1994-05-26 DE DE0706395T patent/DE706395T1/de active Pending
- 1994-05-26 CZ CZ953364A patent/CZ283300B6/cs not_active IP Right Cessation
- 1994-05-26 SG SG1996005829A patent/SG49078A1/en unknown
- 1994-05-26 SK SK1646-95A patent/SK280111B6/sk not_active IP Right Cessation
- 1994-05-26 JP JP50268795A patent/JP3725541B2/ja not_active Expired - Fee Related
- 1994-05-26 DK DK94919912T patent/DK0706395T3/da active
- 1994-05-26 BR BR9406865A patent/BR9406865A/pt not_active Application Discontinuation
- 1994-05-26 US US08/256,319 patent/US5670524A/en not_active Expired - Lifetime
- 1994-05-26 RU RU96101169/14A patent/RU2152215C1/ru not_active IP Right Cessation
- 1994-05-26 PL PL94312198A patent/PL175518B1/pl not_active IP Right Cessation
- 1994-05-26 DE DE69430427T patent/DE69430427T2/de not_active Expired - Lifetime
- 1994-05-26 EP EP94919912A patent/EP0706395B1/en not_active Expired - Lifetime
- 1994-05-26 NZ NZ268110A patent/NZ268110A/xx not_active IP Right Cessation
- 1994-05-26 PT PT94919912T patent/PT706395E/pt unknown
- 1994-05-26 CA CA002165446A patent/CA2165446C/en not_active Expired - Fee Related
- 1994-05-26 CN CN94192664A patent/CN1074918C/zh not_active Expired - Fee Related
- 1994-05-26 HU HU9503692A patent/HU218949B/hu not_active IP Right Cessation
- 1994-05-26 AT AT94919912T patent/ATE216237T1/de not_active IP Right Cessation
- 1994-05-26 WO PCT/SE1994/000496 patent/WO1995000148A1/en active IP Right Grant
- 1994-06-01 TW TW083105008A patent/TW285640B/zh not_active IP Right Cessation
- 1994-06-08 IS IS4174A patent/IS4174A/is unknown
- 1994-06-09 PH PH48413A patent/PH31258A/en unknown
- 1994-06-13 IL IL11000694A patent/IL110006A/en not_active IP Right Cessation
- 1994-06-14 SA SA94150010A patent/SA94150010B1/ar unknown
- 1994-06-17 LT LTIP1958A patent/LT3449B/lt not_active IP Right Cessation
- 1994-06-27 MY MYPI94001663A patent/MY119360A/en unknown
- 1994-11-03 EE EE9400347A patent/EE03205B1/xx not_active IP Right Cessation
-
1995
- 1995-12-27 FI FI956269A patent/FI956269A/fi not_active Application Discontinuation
- 1995-12-27 NO NO955313A patent/NO955313L/no not_active Application Discontinuation
-
1997
- 1997-05-05 US US08/851,062 patent/US5834489A/en not_active Expired - Lifetime
- 1997-05-30 GR GR970300013T patent/GR970300013T1/el unknown
-
1998
- 1998-10-19 HK HK98111303A patent/HK1010344A1/xx not_active IP Right Cessation
-
2002
- 2002-07-15 LV LVP-02-131A patent/LV12918B/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016508956A (ja) * | 2012-05-10 | 2016-03-24 | セリックスビオ プライヴェート リミテッド | 局所疼痛の治療のための組成物と治療法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Stenseth et al. | Epidural morphine for postoperative pain: experience with 1085 patients | |
Leppik et al. | Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients | |
Mecklem et al. | Efficacy of bupivacaine delivered by wound catheter for post‐caesarean section analgesia | |
Acalovschi et al. | Saddle block with pethidine for perineal operations | |
JPH09500620A (ja) | 極小の運動遮断で鎮痛効果を示す医薬の製造におけるロピバカインの使用 | |
EP0236477B1 (en) | Use of 6-methylene-6-desoxy-n-cyclopropylmethyl-14-hydroxydihydronormorphine | |
CA2294950C (en) | Levobupivacaine and its use | |
JP2001526217A (ja) | 血管性頭痛に対する局所麻酔薬の新規な使用 | |
AU692161C (en) | Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade | |
US20020091161A1 (en) | Novel long acting, reversible veterinary sedative & analgesic and method of use | |
EP1762239B1 (en) | Lofexidine for intraspinal administration | |
KR20090103656A (ko) | 섬유근육통 치료제 | |
US20070060632A1 (en) | Lofexidine | |
WO2022175973A1 (en) | An injectable composition for long term delivery of nalbuphine or nalbuphine ester prodrug or its salts and use thereof | |
UA146317U (uk) | Лікарський засіб в парентеральній лікарській формі | |
HU210322B (en) | Process for production of preparations containing ropivacaine for treatment of iontophoresis | |
WO2001097812A1 (fr) | Preparations pharmaceutiques contenant des composes tetracycliques | |
NZ237398A (en) | A synergistic combination of an analgesic and glucagon and its use in the treatment of colic pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031208 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040311 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20040318 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050922 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080930 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090930 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100930 Year of fee payment: 5 |
|
LAPS | Cancellation because of no payment of annual fees |